ACT-RESoLUTE (NCT07414940) enrolls PSMA-positive mCRPC after ≥1 ARPI and 1–2 taxane lines, requiring PSMA-PET avidity, ECOG 0–1, and ≤grade 1 baseline xerostomia. Participants receive ...
A recap of the FDA submissions and regulatory decisions in urology from June 2026. Welcome to Urology Times’® monthly FDA update! June 2026 brought a wave of regulatory developments across the urology ...
A roundup of the key stories across genitourinary cancers from the second quarter of 2026. The second quarter of 2026 brought several practice-changing developments across genitourinary oncology, from ...
Sanoj Punnen, MD, highlights the importance of assessing and managing cardiovascular risk when initiating androgen deprivation therapy for patients with prostate cancer.
CONVERGE-01 enrolled progressive PSMA-positive mCRPC after 1-6 prior Lu-177–PSMA cycles, with universal ARPI exposure and 80% prior taxane use in the ASCO cohort. Fractionated CONV01-α on days 1 and ...
Sanoj Punnen, MD, highlights the importance of assessing and managing cardiovascular risk when initiating androgen deprivation therapy for patients with prostate cancer. Punnen explained that the ...
Tentative FDA approval enables Lupin to prepare for commercial launch of generic enzalutamide once remaining exclusivity and patent constraints no longer block approval. Bioequivalence was established ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results